Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Buy
60
KROS Quote, Financials, Valuation and Earnings
Last price:
$21.28
Seasonality move
:
6.31%
Day range:
$20.26 - $21.93
52-week range:
$9.12 - $72.37
Dividend yield:
0%
P/E ratio:
14.06x
P/S ratio:
3.57x
P/B ratio:
0.94x
Volume:
1.1M
Avg. volume:
1.2M
1-year change:
-66.43%
Market cap:
$660.8M
Revenue:
$3.6M
EPS (TTM):
$1.54
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
KROS
Keros Therapeutics, Inc.
|
$4.2M | -$0.92 | 20.4% | -61.58% | $23.38 |
|
BNGO
Bionano Genomics, Inc.
|
$6.9M | -$2.34 | -2.86% | -82.39% | $7.50 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
KROS
Keros Therapeutics, Inc.
|
$21.69 | $23.38 | $660.8M | 14.06x | $0.00 | 0% | 3.57x |
|
BNGO
Bionano Genomics, Inc.
|
$1.68 | $7.50 | $17.1M | -- | $0.00 | 0% | 0.20x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.21 | $0.85 | $152.5M | 2.03x | $0.80 | 0% | 2.35x |
|
OGEN
Oragenics, Inc.
|
$0.88 | $2.00 | $727K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.23 | $7.00 | $7.6M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
KROS
Keros Therapeutics, Inc.
|
2.42% | 1.402 | 2.71% | 28.93x |
|
BNGO
Bionano Genomics, Inc.
|
25.67% | -1.308 | 103.34% | 1.58x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
KROS
Keros Therapeutics, Inc.
|
$13.9M | -$15.4M | 9.66% | 9.94% | -107.87% | $3.1M |
|
BNGO
Bionano Genomics, Inc.
|
$3.4M | -$8.5M | -58.02% | -84.77% | -115.9% | -$5.9M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Keros Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns KROS or BNGO?
Bionano Genomics, Inc. has a net margin of -51.05% compared to Keros Therapeutics, Inc.'s net margin of -115.42%. Keros Therapeutics, Inc.'s return on equity of 9.94% beat Bionano Genomics, Inc.'s return on equity of -84.77%.
Company Gross Margin Earnings Per Share Invested Capital KROSKeros Therapeutics, Inc.97.23% -$0.18 $721M BNGOBionano Genomics, Inc.45.75% -$1.59 $67M -
What do Analysts Say About KROS or BNGO?
Keros Therapeutics, Inc. has a consensus price target of $23.38, signalling upside risk potential of 7.77%. On the other hand Bionano Genomics, Inc. has an analysts' consensus of $7.50 which suggests that it could grow by 346.43%. Given that Bionano Genomics, Inc. has higher upside potential than Keros Therapeutics, Inc., analysts believe Bionano Genomics, Inc. is more attractive than Keros Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KROSKeros Therapeutics, Inc.6 5 0 BNGOBionano Genomics, Inc.1 0 0 -
Is KROS or BNGO More Risky?
Keros Therapeutics, Inc. has a beta of 0.892, which suggesting that the stock is 10.815% less volatile than S&P 500. In comparison Bionano Genomics, Inc. has a beta of 2.336, suggesting its more volatile than the S&P 500 by 133.592%.
-
Which is a Better Dividend Stock KROS or BNGO?
Keros Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Keros Therapeutics, Inc. pays -- of its earnings as a dividend. Bionano Genomics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KROS or BNGO?
Keros Therapeutics, Inc. quarterly revenues are $14.3M, which are larger than Bionano Genomics, Inc. quarterly revenues of $7.4M. Keros Therapeutics, Inc.'s net income of -$7.3M is higher than Bionano Genomics, Inc.'s net income of -$8.5M. Notably, Keros Therapeutics, Inc.'s price-to-earnings ratio is 14.06x while Bionano Genomics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics, Inc. is 3.57x versus 0.20x for Bionano Genomics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KROSKeros Therapeutics, Inc.3.57x 14.06x $14.3M -$7.3M BNGOBionano Genomics, Inc.0.20x -- $7.4M -$8.5M
-
Which has Higher Returns KROS or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -51.05% compared to Keros Therapeutics, Inc.'s net margin of -255.85%. Keros Therapeutics, Inc.'s return on equity of 9.94% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital KROSKeros Therapeutics, Inc.97.23% -$0.18 $721M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About KROS or NBY?
Keros Therapeutics, Inc. has a consensus price target of $23.38, signalling upside risk potential of 7.77%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -29.75%. Given that Keros Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Keros Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KROSKeros Therapeutics, Inc.6 5 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is KROS or NBY More Risky?
Keros Therapeutics, Inc. has a beta of 0.892, which suggesting that the stock is 10.815% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock KROS or NBY?
Keros Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Keros Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KROS or NBY?
Keros Therapeutics, Inc. quarterly revenues are $14.3M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Keros Therapeutics, Inc.'s net income of -$7.3M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Keros Therapeutics, Inc.'s price-to-earnings ratio is 14.06x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 2.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics, Inc. is 3.57x versus 2.35x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KROSKeros Therapeutics, Inc.3.57x 14.06x $14.3M -$7.3M NBYNovaBay Pharmaceuticals, Inc.2.35x 2.03x $521K -$1.3M
-
Which has Higher Returns KROS or OGEN?
Oragenics, Inc. has a net margin of -51.05% compared to Keros Therapeutics, Inc.'s net margin of --. Keros Therapeutics, Inc.'s return on equity of 9.94% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital KROSKeros Therapeutics, Inc.97.23% -$0.18 $721M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About KROS or OGEN?
Keros Therapeutics, Inc. has a consensus price target of $23.38, signalling upside risk potential of 7.77%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 126.37%. Given that Oragenics, Inc. has higher upside potential than Keros Therapeutics, Inc., analysts believe Oragenics, Inc. is more attractive than Keros Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KROSKeros Therapeutics, Inc.6 5 0 OGENOragenics, Inc.1 0 0 -
Is KROS or OGEN More Risky?
Keros Therapeutics, Inc. has a beta of 0.892, which suggesting that the stock is 10.815% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock KROS or OGEN?
Keros Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Keros Therapeutics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KROS or OGEN?
Keros Therapeutics, Inc. quarterly revenues are $14.3M, which are larger than Oragenics, Inc. quarterly revenues of --. Keros Therapeutics, Inc.'s net income of -$7.3M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, Keros Therapeutics, Inc.'s price-to-earnings ratio is 14.06x while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics, Inc. is 3.57x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KROSKeros Therapeutics, Inc.3.57x 14.06x $14.3M -$7.3M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns KROS or PTN?
Palatin Technologies has a net margin of -51.05% compared to Keros Therapeutics, Inc.'s net margin of --. Keros Therapeutics, Inc.'s return on equity of 9.94% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital KROSKeros Therapeutics, Inc.97.23% -$0.18 $721M PTNPalatin Technologies-- -- -- -
What do Analysts Say About KROS or PTN?
Keros Therapeutics, Inc. has a consensus price target of $23.38, signalling upside risk potential of 7.77%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Keros Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Keros Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KROSKeros Therapeutics, Inc.6 5 0 PTNPalatin Technologies0 0 0 -
Is KROS or PTN More Risky?
Keros Therapeutics, Inc. has a beta of 0.892, which suggesting that the stock is 10.815% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock KROS or PTN?
Keros Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Keros Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KROS or PTN?
Keros Therapeutics, Inc. quarterly revenues are $14.3M, which are larger than Palatin Technologies quarterly revenues of --. Keros Therapeutics, Inc.'s net income of -$7.3M is higher than Palatin Technologies's net income of --. Notably, Keros Therapeutics, Inc.'s price-to-earnings ratio is 14.06x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics, Inc. is 3.57x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KROSKeros Therapeutics, Inc.3.57x 14.06x $14.3M -$7.3M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns KROS or TOVX?
Theriva Biologics, Inc. has a net margin of -51.05% compared to Keros Therapeutics, Inc.'s net margin of --. Keros Therapeutics, Inc.'s return on equity of 9.94% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital KROSKeros Therapeutics, Inc.97.23% -$0.18 $721M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About KROS or TOVX?
Keros Therapeutics, Inc. has a consensus price target of $23.38, signalling upside risk potential of 7.77%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3004.21%. Given that Theriva Biologics, Inc. has higher upside potential than Keros Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Keros Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KROSKeros Therapeutics, Inc.6 5 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is KROS or TOVX More Risky?
Keros Therapeutics, Inc. has a beta of 0.892, which suggesting that the stock is 10.815% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock KROS or TOVX?
Keros Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Keros Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KROS or TOVX?
Keros Therapeutics, Inc. quarterly revenues are $14.3M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Keros Therapeutics, Inc.'s net income of -$7.3M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Keros Therapeutics, Inc.'s price-to-earnings ratio is 14.06x while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics, Inc. is 3.57x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KROSKeros Therapeutics, Inc.3.57x 14.06x $14.3M -$7.3M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 59.64% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 9.18% over the past day.
Sell
13
PSN alert for Dec 8
Parsons Corp. [PSN] is down 5.19% over the past day.
